Brown Shipley& Co Ltd Has $6.54 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Brown Shipley& Co Ltd trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,567 shares of the medical research company's stock after selling 673 shares during the period. Thermo Fisher Scientific makes up approximately 3.2% of Brown Shipley& Co Ltd's investment portfolio, making the stock its 11th largest holding. Brown Shipley& Co Ltd's holdings in Thermo Fisher Scientific were worth $6,538,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of TMO. Norges Bank purchased a new position in Thermo Fisher Scientific in the 4th quarter worth about $3,149,754,000. T. Rowe Price Investment Management Inc. increased its stake in Thermo Fisher Scientific by 86.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock worth $1,604,338,000 after purchasing an additional 1,433,444 shares in the last quarter. Kovitz Investment Group Partners LLC increased its stake in Thermo Fisher Scientific by 1,905.4% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock worth $469,889,000 after purchasing an additional 858,193 shares in the last quarter. Proficio Capital Partners LLC increased its stake in Thermo Fisher Scientific by 68,617.0% in the 4th quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company's stock worth $396,810,000 after purchasing an additional 761,649 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Thermo Fisher Scientific in the 4th quarter worth about $377,901,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Wednesday. Argus decreased their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research report on Tuesday, April 29th. Stifel Nicolaus decreased their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research report on Thursday, April 24th. Finally, Royal Bank of Canada lowered their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average price target of $607.43.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the sale, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. This represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. The trade was a 25.87% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,075 shares of company stock worth $7,305,942. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

NYSE:TMO traded down $6.95 during trading hours on Friday, reaching $393.53. The company had a trading volume of 2,318,052 shares, compared to its average volume of 1,869,410. The stock has a 50-day moving average of $442.54 and a two-hundred day moving average of $504.86. Thermo Fisher Scientific Inc. has a one year low of $390.50 and a one year high of $627.88. The firm has a market capitalization of $148.56 billion, a PE ratio of 23.81, a PEG ratio of 2.99 and a beta of 0.82. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. During the same period in the prior year, the business posted $5.11 earnings per share. The business's revenue was up .2% compared to the same quarter last year. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's payout ratio is presently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.